Bioelectronics Corp (OTCMKTS:BIEL) is soaring up the charts. BIEL is up +200% over the last month and the volume is just as impressive topping out over 180M shares trading hands on average over the last ten days. The catalyst for the jump in price is the upcoming meetings they are set to have with the FDA to take their ActiPatch toward Over the Counter clearance for muscle pain. BIEL already has OTC approval for knee osteoarthritis and plantar fasciitis. Muscle pain is much broader and would lead to increased revenue equaling an important payday for BIEL.
Sree Koneru, Ph.D., VP of Product Development at BIEL, expressed confidence in the upcoming meetings and in the strength of the clinical evidence. “The clinical studies that were submitted have been conducted in an independent and rigorous manner, so we are looking forward to working with the FDA and seek their guidance to obtain expanded market clearances in a timely manner,” Mr. Whelan said.
Bioelectronics Corp (OTCMKTS:BIEL) is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy.
According to the company, BIEL is a development-stage company. The Company is a developer, marketer, and manufacturer of non-invasive electroceutical medical devices. Its devices consist of a microchip, battery, and antenna, and use therapies of heat and electric restoration of the body’s injured cells. Its devices are used to treat acute and chronic pain, as well as to promote wound healing. Its products include, as mentioned above, ActiPatch for Musculoskeletal Pain, Smart Insole for Foot Care, Allay for Menstrual Pain, RecoveryRx for Chronic Wounds and Postoperative Recovery, and HealFast for cats, dogs and horses. ActiPatch is a pain therapy for a range of common conditions causing pain, including osteoarthritis, rheumatoid arthritis and fibromyalgia. Its Smart Insole consists of Electro-Pulse micro medical devices that are embedded in heel gel inserts. Its Allay is a micro medical device that uses Electromagnetic Pulse Therapy to reduce menstrual pain and discomfort.
Find out when $BIEL stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The Maryland-based company’s technology is rooted in something called neuromodulation. Neuromodulation is a term that describes the direct stimulation of the nervous system (or in other words, nerves) through electrical impulse. ActiPatch employs this type of neuromodulation therapy approach to target what it calls muscoskeletal pain, which is another way to describe muscle and back pain. At core, the product fires electrical signals from a patch to the nerves of the patient, and this regulates the electrical activity of nerves. This regulation, in turn, relieves pain.
The FDA is not so hesitant to approve these over the counter therapies because no chemical alteration in the body takes place. So, in short, investors are prediciting that this is a slam dunk for ActiPatch.
A second meeting will take place on May 29th, 2018 to seek expanded indications for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device. BioElectronics currently has a prescription-only clearance for the treatment of edema following blepharoplasty (eye-lid corrective surgery).
Bioelectronics Corp (OTCMKTS: BIEL) has a market cap of $68.69M and outstanding shares of 18.08B. The market is strategizing around BIEL as FDA-approval looms for this alternative pain relief that has become quite popular as the opioid epidemic ravages communities and words spread about its dangers. This is an exciting story and we will be writing updates soon. For continuing coverage on shares of $BIEL stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $BIEL, either long or short, and we have not been compensated for this article.